Amulet Capital Partners announced on May 22 its acquisition of Alliance Clinical Network (ACN) for an undisclosed price. According to data captured in the LevinPro HC database, this acquisition marks the 11th clinical trials transaction of the year.
Headquartered in Dallas, Texas, ACN is a comprehensive clinical site platform. ACN currently owns and operates six clinical research sites serving patients, leading pharmaceutical sponsors and contract research organizations across three states (California, Nevada and Texas).
With a focus on Phase II and Phase III general medicine trials and a demonstrated expertise in enrolling diverse patient populations, ACN services a range of clinical therapeutic areas, including dermatology, gastroenterology, neurology, pain, vaccines and women’s health. In 2022, the company supported more than 75 unique clinical trials for more than 40 sponsors.
Amulet Capital Partners is a middle-market private equity investment firm focused exclusively on the healthcare sector. Its target investment size is generally between $25 million to $150 million.
ACN will continue to be led by its Founder and CEO Anthony Abey, who will retain a significant ownership stake in the business. In partnership with Amulet, ACN intends to strategically expand its footprint – both through continued de novo development and strategic acquisitions – while building on its strong presence in vaccines and enhancing its capabilities in other therapeutic areas.
Cantor Fitzgerald served as exclusive financial advisor to CAN, while Amulet was advised by Harris Williams.
